Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis

: Pharmacokinetics of Ceftazidime-Avibactam in Critically Ill Patients With Renal Failure Requiring Continuous Venovenous Hemodiafiltration

The study's primary objective is to determine plasma and dialysis fluid concentrations in patients prescribed ceftazidime-avibactam as the standard treatment for their infection and requiring continuous venovenous hemodiafiltration (CVVHDF) as part of the standard treatment for acute or chronic renal failure. Secondarily, the study will evaluate the pharmacokinetics of ceftazidime-avibactam in these patients on CVVHDF. The study will also determine if the prescribed dose meets pharmacodynamic targets.

Inclusion Criteria:

• Adults > 18 years of age
• Patients requiring continuous renal replacement therapy (CRRT) due to acute or chronic renal failure
• documented or suspected infection requiring a prescription for ceftazidime-avibactam

Exclusion Criteria:

• Patients on CRRT < 24 hours
• Patients on ceftazidime-avibactam < 24 hours
• Patients unable to remain on CRRT for 32 hours continuously without clotting